not registered? click here



Current Therapies
    In Vitro
    In Vivo



In order to analytically validate the efficacy and safety of the MBP system, PKC has conducted in vitro tests to explore system capabilities and limitations associated with flow rate, volume, duration, power consumption, wireless communication, repeatability, reliability and various artificial intelligence (AI) routines controlling and regulating the performance of the MBP apparatus. To that effect PKC will undertake the effort of designing, developing and implementing a rigorous and statistically significant bench test complementing the animal study. These tests will be used to validate the assumption of an improved diffusion model using local delivery of medicating agents under the regimens of the MBP schedule using the following end points:


  • Accuracy – demonstration of the MBP’s ability to locally deliver the medicating agent so as to regulate the volume and schedule.


  • Close-loop feedback – demonstration of the MBP’s ability to regulate the amount of medicating agent delivered based on parameters such as VEGF levels in a simulated environment as detected by the UV LED spectrometer.


    The objective of the in vitro study is to test the performance, efficacy and safety of the MBP under analytical conditions relative to these primary end points. The primary safety endpoints are defined as the absence of structural abnormalities, adverse events and cases of brain injuries due to inadequate performance of the MBP apparatus. We intend to employ radiopaque contrast agents such as iopamidol (Isovue-370) simulating pharmacodynamic conditions so as to enable X-ray video (Ziehm Vision FD Imaging systems) to continuously monitor the diffusion model. We expect this method to demonstrate the ability of MBP to accurately dispense the medicating agents by measuring surface area and absorption rate.


    Invitro Test Illustration

      main: 310.641.2700 fax: 310.641.2702 6053 W Century Blvd, Suite 1000, Los Angeles, CA 90045-6400 © Pharmaco Kinesis Corp.